title: Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
abstract: To further find effective method to improve the long term survival of refractory or relapsed acute myeloid leukemia (AML) patients, we retrospectively analyzed the outcomes of myeloablative hematopoietic stem cell transplantation (HSCT) for 133 consecutive patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) therapy related AML(t-AML) in not remission status. The overall 3-year OS and DFS were 40.9% and 35.6% respectively. The variables associated with improved long term DFS were a bone marrow blast cell count less than 20% and an intensified conditioning regimen. In addition, the t-AML group had higher rates of relapse and III-IV acute GVHD than the primary AML group. The unrelated donor group had similar OS and DFS with sibling groups. Our study suggested that decreasing bone marrow blast cell counts before HSCT and strengthening the conditioning regimen may improve long-term DFS for refractory/relapsed AML patients, and unrelated donor group can get similar effect when compared to the sibling group.
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Na
authors.initials: N
authors.lastname: Liu
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Ning
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Liang-Ding
authors.initials: LD
authors.lastname: Hu
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Chen
authors.initials: C
authors.lastname: Xu
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Jiang-Wei
authors.initials: JW
authors.lastname: Hu
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Yu-Hang
authors.initials: YH
authors.lastname: Li
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Bo-Tao
authors.initials: BT
authors.lastname: Li
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Lou
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Fan
authors.initials: F
authors.lastname: Yang
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Jian-Lin
authors.initials: JL
authors.lastname: Chen
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Yong-Feng
authors.initials: YF
authors.lastname: Su
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Meng
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Hong-Ye
authors.initials: HY
authors.lastname: Wang
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Jing
authors.initials: J
authors.lastname: Ren
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Yue-Qian
authors.initials: YQ
authors.lastname: Feng
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China.
authors.forename: Dan-Hong
authors.initials: DH
authors.lastname: Wang
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation Center, Affiliated Hospital to Academy of Military Medical Science (307Hospital, PLA), China. Electronic address: chenhu217@aliyun.com.
authors.forename: Hu
authors.initials: H
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D064591:Allografts; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006648:Histocompatibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D019520:Living Donors; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D014411:Neoplastic Stem Cells; D036102:Peripheral Blood Stem Cell Transplantation; D012008:Recurrence; D012189:Retrospective Studies; D035781:Siblings; D019172:Transplantation Conditioning / Q000379:methods* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists
keywords: Acute myeloid leukemia; Blast cells; Hematopoietic stem cell transplantation; Intensified conditioning regimen; Myelodysplastic syndrome; Refractory